Impact Biomedical, Inc. · AMEX:IBO
Impact Biomedical — Investor Presentation (August 2024)
16 slides from Impact Biomedical's investor presentation, August 2024
Slide 1: New Solutions in Human Health and Wellness
NEW SOLUTIONS IN HUMAN HEALTH AND WELLNESS www.ImpactBiomedInc.com August 2024
Slide 2: Safe Harbor
SAFE HARBOR This presentation contains certain forward-looking statements within the meaning of the federal securities laws. These statements may be made a part of this presentation or by reference to other documents we file with the SEC. Some of the forward-looking statements can be identified by t
Slide 3: Executive Summary
EXECUTIVE SUMMARY Impact Biomedical Inc. (IBIO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationshi
Slide 4: Core Technologies
LINEBACKER LineBacker is a platform electrophilically enhanced polyphenols to induce potency, efficacy, and bioavailability, without compromising safety standards. EQUIVIR Equivir technology is a novel blend of FDA Generally Recognized as Safe (GRAS) eligible polyphenols that have demonstrated antiv
Slide 5: Linebacker (LB)
LINEBACKER (LB) Modified Myricetin, a plant derived flavonoid that exhibits strong antioxidant, anti-cancer, anti-diabetic, and anti-inflammatory activities. LINEBACKER THERAPEUTIC POTENTIAL* DEVELOPMENT / IP ● LB-1: Potential Co-therapy (Colon/Lung): CANCER ● Down regulates PIM (proviral integratio
Slide 6: Equivir /G (Flavonoids)
EQUIVIR /G (FLAVONOIDS) ● Two Discreet Products With Novel blend of generally recognized as safe (GRAS) polyphenols. ● Polyphenol blend: ■ Myricetin ■ Piperine ■ Hesperitin ■ Gallic Acid APPLICATIONS / INDICATION NATURALLY-SOURCED ORIGIN DEVELOPMENT / IP Composition and Method Patents ● Antiviral In
Slide 7: 3F Functional Fragrances
3F FUNCTIONAL FRAGRANCES ● Suite of “functional fragrances” containing specialized botanical ingredients (e.g., terpenes) with potential application as an antiviral or as an insect repellent(e.g. mosquito). ● Fragrances can also be applied to laundry detergents, shampoos, and lotions to provide addi
Slide 8: Laetose
Laetose ● Unique combination of multiple sugars independently with inositol, which demonstrates the ability to inhibit the inflammatory and metabolic response of sugar alone. Laetose ● Could result in reducing caloric intake and glycemic index in foods. APPLICATIONS / INDICATION DEVELOPMENT STATUS I
Slide 9: Intellectual Property
3 Patents Issued 9 Patents Pending Linebacker INTELLECTUAL 3 Patents Issued PROPERTY 13 Patents Pending PATENTS ISSUED AND PATENTS PENDING 8 Issued U.S. Patents 3F 1 Patents Issued 40+ Patents Pending 26 Patents Pending Laetose 1 Patents Issued 10 Patents Pending www.ImpactBiomedInc.com 9
Slide 10: Why Invest in Impact Biomedical?
Attractive Valuation/Potential Shareholder Appreciation Unique Early-Stage Healthcare Company: ● Bio-tech/Med-Tech Regulated WHY INVEST IN ● Consumer (OTC) IMPACT Novel Intellectual Property Worldwide: ● Eight (8) Issued Patents ● More than Forty (40) Pending Patents BIOMEDICAL? Potential Near-Term
Slide 11: Executive Officers
EXECUTIVE OFFICERS Frank D. Heuszel Todd Macko Mark Suseck CEO CFO COO www.ImpactBiomedInc.com 11
Slide 12: Board of Directors
BOARD OF DIRECTORS Frank D. Heuszel Executive Chairman Frank D. Heuszel has served as President and Director of the Company since August 2020. Since April 2023, Mr. Heuszel has also served as Chief Executive Officer of the Company. Mr. Heuszel has served as the Chief Executive Officer of DSS since A
Slide 13: Board of Directors
BOARD OF DIRECTORS Dr. Elise Brownell Dr. Elise Brownell, Ph.D has served as a director of the Company since January 2021. Dr. Brownell has more than 20 years of biotechnology and pharmaceutical project management experience with a proven track record of advancing programs through clinical developme
Slide 14: Board of Directors
BOARD OF DIRECTORS Castel Hibbert Castel Hibbert has served as director of the company since September 2023. Mr. Hibbert is originally from Detroit, Michigan and has been in Texas since 1981. He attended Michigan State University where he earned a B.A. degree in Employee Relations and a M.B.A. from
Slide 15: Board of Directors
BOARD OF DIRECTORS Chris Zimmerman Christian Zimmerman is currently the CFO of Keystone Bank, SSB, a community bank located in Austin, Texas. Christian has over 17 years of experience in roles of increasing responsibility in the banking and financial industry, including Controller and CFO for both p
Slide 16: For More Information Contact
www.ImpactBiomedInc.com FOR MORE INFORMATION CONTACT: FRANK D. HEUSZEL, President & CEO fheuszel@impactbiomedinc.com / +1 (281) 415-6576
Impact Biomedical — Investor Presentation (August 2024) on 6ix